S&P 5007,482.58▼0.3% Nasdaq25,870.65▲0.2% Dow52,348.09▼1.1% Russell 2K2,948.91▼1.1% 10-Yr4.57%+4bp VIX16.86+0.73 WTI$74.03▲5.1% Gold$4,091.40▼1.3% EUR/USD1.143▼0.1% BTC$63,168▲1.5% Nikkei68,257▼2.1%
At close · Thu, Jul 9, 2026
Daily Market Updates.

Earnings

Home›Earnings›Previews›AstraZeneca shares fall after heart drug trial misses…

AstraZeneca shares fall after heart drug trial misses primary endpoint

Reported · Written up by our desk · Previews

CNBC reports AstraZeneca shares fell about 9% after a late-stage clinical trial failed to miss its primary endpoint.

According to CNBC, the U.K. drugmaker said Thursday that the heart drug trial did not meet its primary endpoint.

← Newer storyAI industry PACs push competing election regulation approaches

More like this

EarningsKeyBanc downgrades Salesforce amid doubts about AI narrative
EarningsAirline earnings head into the next earnings cycle
EarningsDrugmaker sheds $27 billion in market value after failed trial
EarningsAstraZeneca shares fall after heart drug trial misses target
EarningsFedEx Freight discusses results on its first earnings call as a standalone

Sources

CNBC MarketsAstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhouse
CNBC WorldAstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhouse

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.